Top Markets
#1 TENDIES TENDIES +83.50%
#2 Akedo Akedo +81.98%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +43.77%
#5 MultiversX MultiversX +34.16%
#6 Mubarak Mubarak +31.37%
#7 Cash Cat Cash Cat +25.34%
#8 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
#9 Bitway Bitway +16.42%
#10 OSK OSK +16.18%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Nevro Corp. Nevro Corp.

Nevro Corp.

NVRO
Rank in Stocks #17833
Nevro Corp. is a medical technology firm that delivers solutions for... Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.
Share Price
$5.84
Last synced: 2025-04-02
Market Cap
$224.09M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Nevro Corp. (NVRO)

Category

Healthcare
P/E ratio for Nevro Corp. (NVRO)
P/E ratio as of September 2026 TTM: -1.91
According to Nevro Corp. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.91. At the end of 2023 the company had a P/E ratio of -8.40.
P/E ratio history for Nevro Corp. from 2012 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -1.91 56.43%
2024 -1.22 -85.52%
2023 -8.40 -101.80%
2022 466.04 -2,268.47%
2021 -21.49 -69.38%
2020 -70.18 100.98%
2019 -34.92 47.02%
2018 -23.75 -57.14%
2017 -55.42 -14.92%
2016 -65.13 144.73%
2015 -26.61 375.48%
2014 -5.60 750.36%
2013 -0.66 -27.09%
2012 -0.90 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.48 -1,959.17%
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 33.28 -1,843.70%
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -1,220.66%
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 19.48 -1,120.48%
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.16 -2,832.78%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.